TLSA revenueFY2025$1.15M
- FY YoY
- +0.0%
TLSA revenue was $1.15M for fiscal 2025 (ended Dec 31, 2025), up 0.0% from fiscal 2024.
Tiziana Life Sciences Ltd. (TLSA) financials
For fiscal 2025 (ended Dec 31, 2025), Tiziana Life Sciences Ltd. reported $1.15M of revenue and -$18.43M of net income.
- Revenue, FY2025
- $1.15M
- Revenue growth, YoY
- +0.0%
- Net income, FY2025
- -$18.43M
- Net margin
- -1602.7%
- Free cash flow, FY2025
- -$12.87M
- EPS, diluted, FY2025
- -$0.16
- Cash
- $4.01M
- P/S
- 67.41
- Market cap
- $77.5M
FY2024FY2025
FY2016FY2025
FY2017FY2025
TLSA revenue and earnings growth
TLSA net incomeFY2025-$18.43M
TLSA net income was -$18.43M for fiscal 2025 (ended Dec 31, 2025), compared with -$11.86M in fiscal 2024.
TLSA EPSFY2025-$0.16
TLSA diluted EPS was -$0.16 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.11 in fiscal 2024.
TLSA free cash flowFY2025-$12.87M
TLSA free cash flow was -$12.87M for fiscal 2025 (ended Dec 31, 2025), compared with -$1.54M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.15M | $1.15M | - | - | - | - | - | - | - | - |
| Research and development | $10.28M | $5.23M | $8.11M | $12.96M | $13.21M | $5.99M | $3.71M | $5.51M | $6.01M | $4.01M |
| Selling, general and admin | - | - | - | - | - | - | - | $4.42M | $4.60M | $5.87M |
| Operating income | -$21.13M | -$15.79M | -$17.98M | -$14.59M | -$27.37M | -$28.03M | -$9.92M | -$9.87M | -$10.49M | -$9.88M |
| Interest expense | $18.0K | $1.77M | $412.0K | $876.0K | - | - | $92.0K | $12.0K | $12.0K | $12.0K |
| Pre-tax income | -$18.43M | -$16.75M | -$17.24M | -$15.40M | -$26.66M | -$28.34M | -$10.01M | -$9.88M | -$10.51M | -$9.89M |
| Income tax | - | -$4.88M | $449.0K | - | -$3.24M | -$2.21M | -$2.21M | -$1.95M | -$1.91M | -$121.0K |
| Net income | -$18.43M | -$11.86M | -$17.69M | -$15.40M | -$23.42M | -$26.13M | -$9.32M | -$7.93M | -$8.59M | -$9.77M |
| EPS, basic | -$0.16 | -$0.11 | -$0.17 | -$0.15 | -$0.24 | -$0.16 | -$0.07 | -$0.06 | -$8.59 | -$11.35 |
| EPS, diluted | -$0.16 | -$0.11 | -$0.17 | -$0.15 | -$0.24 | -$0.16 | - | - | - | - |
| Diluted shares | 118.3M | 106.7M | 102.5M | 101.5M | 97.9M | 97.3M | 97.3M | 127.6M | 106.4M | 93.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.01M | $3.72M | $1.18M | $18.12M | $42.19M | $65.82M | $200.0K | $5.30M | $64.0K | $5.80M |
| Current assets | $8.55M | $7.51M | $7.34M | $24.28M | $48.68M | $70.18M | $1.50M | $6.91M | $2.45M | - |
| Total assets | $11.49M | $11.28M | $12.18M | $26.48M | $48.83M | $70.66M | $2.38M | $6.92M | $2.47M | - |
| Current liabilities | $11.21M | $7.35M | $6.54M | $6.66M | $7.55M | $7.98M | $7.35M | $6.40M | $4.75M | - |
| Total debt | - | - | - | - | - | $324.0K | $313.0K | $302.0K | $290.0K | $278.0K |
| Total liabilities | $11.44M | $7.35M | $6.65M | $6.91M | $7.55M | $8.27M | $7.89M | $6.40M | $4.75M | - |
| Shareholders' equity | $52.0K | $3.94M | $5.54M | $19.57M | $41.28M | $62.39M | $69.63M | $75.77M | -$2.28M | $4.09M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.85M | -$1.53M | -$15.70M | -$19.61M | -$21.76M | -$11.34M | -$6.80M | -$4.60M | -$7.53M | - |
| Capital expenditures | $21.0K | $19.0K | - | - | $22.0K | $3.0K | $4.0K | - | $1.0K | $48.0K |
| Free cash flow | -$12.87M | -$1.54M | - | - | -$21.78M | -$11.34M | -$6.80M | - | -$7.53M | - |
| Investing cash flow | $3.04M | -$71.0K | -$1.25M | -$4.00M | $130.0K | -$123.0K | -$4.0K | - | -$1.0K | -$342.0K |
| Financing cash flow | $10.01M | $4.50M | $40.0K | -$55.0K | -$23.0K | $75.35M | $1.68M | $10.09M | $1.54M | $1.57M |
| Stock-based compensation | $1.95M | $910.0K | - | - | - | $26.0K | $1.27M | $672.0K | $539.0K | $1.26M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 0.0% | - | - | - | - | - | - | - | - | - |
| Operating margin | -1837.6% | -1373.4% | - | - | - | - | - | - | - | - |
| Net margin | -1602.7% | -1031.6% | - | - | - | - | - | - | - | - |
| Free cash flow margin | -1119.0% | -134.3% | - | - | - | - | - | - | - | - |
| Return on equity | -35444.2% | -301.4% | -319.6% | -78.7% | -56.7% | -41.9% | -13.4% | -10.5% | - | -239.0% |
| Return on assets | -160.3% | -105.1% | -145.2% | -58.2% | -48.0% | -37.0% | -392.1% | -114.7% | -347.8% | - |
| Current ratio | 0.76 | 1.02 | 1.12 | 3.64 | 6.45 | 8.79 | 0.20 | 1.08 | 0.52 | - |
| Debt to equity | - | - | - | - | - | 0.01 | 0.00 | 0.00 | - | 0.07 |
Source: XBRL data Tiziana Life Sciences Ltd. files with the SEC, latest filing dated May 1, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
TLSA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TLSA | $1.15M | +0.0% | -$18.43M | -1602.7% | $77.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
TLSA FAQ
8 questionsWhat is TLSA revenue?
Tiziana Life Sciences Ltd. (TLSA) reported $1.15M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 0.0% from the year before.Is TLSA profitable?
No. Tiziana Life Sciences Ltd. reported a net loss of $18.43M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does TLSA have?
Tiziana Life Sciences Ltd. reported $4.01M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is TLSA revenue growing?
Tiziana Life Sciences Ltd.'s revenue changed +0.0% in fiscal 2025, to $1.15M.What is TLSA free cash flow?
Tiziana Life Sciences Ltd. generated -$12.87M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$12.85M less capital expenditures.What is TLSA earnings per share?
Diluted earnings per share were -$0.16 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did TLSA last report financial results?
The latest statements here come from Tiziana Life Sciences Ltd.'s 20-F filed on May 1, 2026, covering the period ended Dec 31, 2025.Where does this TLSA financial data come from?
Quantisnow builds these statements from the structured XBRL data Tiziana Life Sciences Ltd. files with the SEC. It is provided for information only and is not investment advice.